CIBC World Market
PLX icon

CIBC World Market’s Protalix BioTherapeutics PLX Stock Holding History

CIBC World Market’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,000
Closed -$52K – 1292
2023
Q1 		$52K Sell
25,000
-11,000
-31% -$19.3K ﹤0.01% 1202
2022
Q4 		$49K Buy
+36,000
New +$39.5K ﹤0.01% 1216

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIBC World Market's PLX Position: Q2 2023 in Review

CIBC World Market sold out of Protalix BioTherapeutics (PLX) in Q2 2023, closing a stake of 25,000 shares — an estimated $52K sold.

CIBC World Market first reported a position in PLX in Q4 2022 and held it in 2 quarters. The position peaked at $52K in Q1 2023. 66 funds tracked by Wall St. Rank hold PLX as of Q2 2023.

  • CIBC World Market reported no remaining Protalix BioTherapeutics position as of Q2 2023 after selling out during the quarter.
  • CIBC World Market sold 25,000 Protalix BioTherapeutics shares in Q2 2023, an estimated $52K.
  • CIBC World Market first reported a position in Protalix BioTherapeutics in Q4 2022 and held it in 2 quarters.
  • CIBC World Market's Protalix BioTherapeutics position peaked at $52K in Q1 2023.
  • 66 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2023.

Based on CIBC World Market's 13F filing for Q2 2023, filed 11 Aug 2023.